Patent intelligence · US
US 11246950
Combination cancer immunotherapy with pentaaza macrocyclic ring complex
Combination cancer immunotherapy with pentaaza macrocyclic ring complex
Patent details — US 11246950
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 15, 2022
- Expiration
- Feb 10, 2042
- Applicant
- Galera Labs, LLC
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/55511, A61K2039/585
Quick answer
US 11246950 (Combination cancer immunotherapy with pentaaza macrocyclic ring complex) is held by Galera Labs, LLC. Status: granted. Granted Feb 15, 2022. Expires Feb 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Galera Labs, LLC
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/55511, A61K2039/585, A61K31/555, A61K33/32
More from Galera Labs, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12220420
Combination therapy for cancer treatment
granted -
US 12156863
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
granted -
US 12077549
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 11826373
Methods for treatment of diseases
granted -
US 11612608
Methods of treating oral mucositis
granted -
US 11219614
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
granted -
US 11066433
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted
Frequently asked questions
What is US patent 11246950?
US 11246950 (Combination cancer immunotherapy with pentaaza macrocyclic ring complex) is held by Galera Labs, LLC. Status: granted. Granted Feb 15, 2022. Expires Feb 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11246950?
Galera Labs, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 11246950 expire?
Our index shows an expiration date of Feb 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.